Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Sees Significant Decrease in Short Interest

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totaling 17,654 shares, a decrease of 55.4% from the May 31st total of 39,619 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 100,034 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

Separately, Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Otsuka Price Performance

Shares of OTSKY traded down $0.62 during trading hours on Tuesday, reaching $33.44. 41,901 shares of the stock traded hands, compared to its average volume of 39,832. The company has a market cap of $35.92 billion and a P/E ratio of 14.11. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average price is $34.45 and its two-hundred day moving average price is $32.65. Otsuka has a 52-week low of $21.68 and a 52-week high of $37.52.

Otsuka (OTCMKTS:OTSKY) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, analysts anticipate that Otsuka will post 1.98 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.